We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
- Authors
Maccubbin, D; Bays, H E; Olsson, A G; Elinoff, V; Elis, A; Mitchel, Y; Sirah, W; Betteridge, A; Reyes, R; Yu, Q; Kuznetsova, O; Sisk, C McCrary; Pasternak, R C; Paolini, J F
- Abstract
Improving lipids beyond low-density lipoprotein cholesterol (LDL-C) lowering with statin monotherapy may further reduce cardiovascular risk. Niacin has complementary lipid-modifying efficacy to statins and cardiovascular benefit, but is underutilised because of flushing, mediated primarily by prostaglandin D(2) (PGD(2)). Laropiprant (LRPT), a PGD(2) receptor (DP1) antagonist that reduces niacin-induced flushing has been combined with extended-release niacin (ERN) into a fixed-dose tablet.
- Publication
International journal of clinical practice, 2008, Vol 62, Issue 12, p1959
- ISSN
1742-1241
- Publication type
Journal Article
- DOI
10.1111/j.1742-1241.2008.01938.x